Xilio Therapeutics, Inc. Financing Cash Flow
Xilio Therapeutics, Inc. (XLO) reported Financing Cash Flow of $40.20 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-08-12
- Xilio Therapeutics, Inc. net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was $4.49M, a 90.51% decline year-over-year.
- Xilio Therapeutics, Inc. net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was $35.71M, a 638.97% increase year-over-year.
- Xilio Therapeutics, Inc. net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was $35.87M, a 337.28% increase year-over-year.
- Xilio Therapeutics, Inc. net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was -$285.00K.
- Xilio Therapeutics, Inc. net cash provided by (used in) financing activities for fiscal 2025 was $87.78M, a 200.64% increase from fiscal 2024.
- Xilio Therapeutics, Inc. net cash provided by (used in) financing activities for fiscal 2024 was $29.20M.
- Xilio Therapeutics, Inc. net cash provided by (used in) financing activities for fiscal 2023 was -$6.55M.
- Xilio Therapeutics, Inc. net cash provided by (used in) financing activities for fiscal 2022 was -$69.00K, a 100.03% decline from fiscal 2021.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $4.49M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $40.20M 10-Q · filed 2026-08-12 | $76.07M derived: sum of 3 quarters · filed 2026-08-12 | $75.78M derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | $35.71M 10-Q · filed 2026-05-12 | $71.57M derived: sum of 2 quarters · filed 2026-05-12 | $71.29M derived: sum of 3 quarters · filed 2026-05-12 | $118.65M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | $35.87M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | $35.58M derived: sum of 2 quarters · filed 2026-03-23 | $82.94M derived: sum of 3 quarters · filed 2026-08-12 | $87.78M 10-K · filed 2026-03-23 |
| 2025-09-30 | -$285.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $47.08M derived: sum of 2 quarters · filed 2026-08-12 | $51.91M 10-Q · filed 2025-11-13 | $60.11M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | $47.36M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $52.19M 10-Q · filed 2026-08-12 | $60.40M derived: sum of 3 quarters · filed 2026-08-12 | $60.39M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | $4.83M 10-Q · filed 2026-05-12 | $13.03M derived: sum of 2 quarters · filed 2026-05-12 | $13.03M derived: sum of 3 quarters · filed 2026-05-12 | $33.07M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $8.20M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | $8.20M derived: sum of 2 quarters · filed 2026-03-23 | $28.24M derived: sum of 3 quarters · filed 2026-03-23 | $29.20M 10-K · filed 2026-03-23 |
| 2024-09-30 | -$3.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $20.04M derived: sum of 2 quarters · filed 2025-11-13 | $20.99M 10-Q · filed 2025-11-13 | $19.36M derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | $20.04M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $21.00M 10-Q · filed 2025-08-14 | $19.36M derived: sum of 3 quarters · filed 2025-08-14 | $17.13M derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | $954.00K 10-Q · filed 2025-05-08 | -$680.00K derived: sum of 2 quarters · filed 2025-05-08 | -$2.92M derived: sum of 3 quarters · filed 2025-05-08 | -$3.91M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | -$1.63M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11 | -$3.87M derived: sum of 2 quarters · filed 2025-03-11 | -$4.86M derived: sum of 3 quarters · filed 2025-03-11 | -$6.55M 10-K · filed 2025-03-11 |
| 2023-09-30 | -$2.24M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | -$3.23M derived: sum of 2 quarters · filed 2024-11-07 | -$4.92M 10-Q · filed 2024-11-07 | -$4.94M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | -$992.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | -$2.68M 10-Q · filed 2024-08-08 | -$2.70M derived: sum of 3 quarters · filed 2024-08-08 | -$2.72M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | -$1.69M 10-Q · filed 2024-05-14 | -$1.71M derived: sum of 2 quarters · filed 2024-05-14 | -$1.73M derived: sum of 3 quarters · filed 2024-05-14 | -$1.75M derived: sum of 4 quarters · filed 2024-05-14 |
| 2022-12-31 | -$21.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01 | -$43.00K derived: sum of 2 quarters · filed 2024-04-01 | -$64.00K derived: sum of 3 quarters · filed 2024-04-01 | -$69.00K 10-K · filed 2024-04-01 |
| 2022-09-30 | -$22.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | -$43.00K derived: sum of 2 quarters · filed 2023-11-09 | -$48.00K 10-Q · filed 2023-11-09 | $115.78M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | -$21.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | -$26.00K 10-Q · filed 2023-08-14 | $115.80M derived: sum of 3 quarters · filed 2023-08-14 | $116.10M derived: sum of 4 quarters · filed 2023-08-14 |
| 2022-03-31 | -$5.00K 10-Q · filed 2023-05-09 | $115.82M derived: sum of 2 quarters · filed 2023-05-09 | $116.12M derived: sum of 3 quarters · filed 2023-05-09 | $115.77M derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | $115.83M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-02 | $116.13M derived: sum of 2 quarters · filed 2023-03-02 | $115.78M derived: sum of 3 quarters · filed 2023-03-02 | $260.67M 10-K · filed 2023-03-02 |
| 2021-09-30 | $301.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | -$48.00K derived: sum of 2 quarters · filed 2022-11-09 | $144.84M 10-Q · filed 2022-11-09 | $144.97M derived: sum of 4 quarters · filed 2022-11-09 |
| 2021-06-30 | -$349.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $144.54M 10-Q · filed 2022-08-09 | $144.67M derived: sum of 3 quarters · filed 2022-08-09 | |
| 2021-03-31 | $144.89M 10-Q · filed 2022-05-12 | $145.01M derived: sum of 2 quarters · filed 2022-05-12 | ||
| 2020-12-31 | $125.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $10.03M 10-K · filed 2022-03-01 | ||
| 2020-09-30 | $9.90M 10-Q · filed 2021-12-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Annovis Bio, Inc. (ANVS) | United States | $0.056B | -1.58 |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 |